Bocidelpar + Placebo
Phase 1Terminated 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Reduced Maximum Oxygen Uptake Due to Poor Systemic Oxygen Extraction
Conditions
Reduced Maximum Oxygen Uptake Due to Poor Systemic Oxygen Extraction
Trial Timeline
Jun 14, 2021 → Dec 16, 2022
NCT ID
NCT04855201About Bocidelpar + Placebo
Bocidelpar + Placebo is a phase 1 stage product being developed by Astellas Pharma for Reduced Maximum Oxygen Uptake Due to Poor Systemic Oxygen Extraction. The current trial status is terminated. This product is registered under clinical trial identifier NCT04855201. Target conditions include Reduced Maximum Oxygen Uptake Due to Poor Systemic Oxygen Extraction.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04855201 | Phase 1 | Terminated |
| NCT04641962 | Phase 2 | Terminated |
| NCT04184882 | Phase 1 | Terminated |
Competing Products
20 competing products in Reduced Maximum Oxygen Uptake Due to Poor Systemic Oxygen Extraction